SEC Form 4 · accession 0001178913-18-001112
Foamix Pharmaceuticals Ltd. · FOMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Russell P. Elliott
Officer — VP Drug Development
Period of report
Apr 2, 2018
Accepted (ET)
Apr 4, 2018 · 12:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001606645
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Apr 2, 2018 | S | 142 | $5.08 | D | 12,726 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of re-stricted share units. This sale is mandated by the Issuer's non-discretionary policy that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.